ArticleBMC cancer2026
Survival of myelodysplastic syndrome patients after azacitidine therapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy.BMC cancer · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough azacitidine monotherapy improves survival in myelodysplastic (MDS) patients, various outcomes have been found regarding cytogenetic and molecular features.
methodsThis retrospective analysis of 80 Thai patients with MDS treated with azacitidine monotherapy evaluated real-world outcomes in Thailand and identified clinical parameters associated with treatment response and survival. Azacitidine was given at 100 mg/day for 7 days, every 28-day cycle. Targeted exome analysis of 25 genes was performed, using a QIAact Myeloid DNA UMI Panel with GeneReader next generation sequencing system.
resultsMDS with increased blasts (IB) and low blasts (LB) were observed in 64% and 20%, respectively. The median number of cycles of azacitidine therapy was 11 cycles. The ORR was 59%, patients with MDS-IB2 had the highest ORR (71%) compared to those with MDS-IB1 (47%) or MDS-LB (41%), p = 0.029. A significantly lower ORR was found for MDS patients (27%) with complex karyotypes (CKs), p = 0.016. MDS patients with poor/very poor risk cytogenetics had significantly lower ORR than those without poor/very poor risk cytogenesis 37% versus 65%, p = 0.039. MDS patients with mutated TET2 had lower ORR than those with wild-type TET2, 17% vs. 62% (p = 0.041). The median OS in patients with MDS was 19 months. The median OS was shorter in MDS patients with CKs (p = 0.003), intermediate/higher-risk IPSS-R (p = 0.046), poor- cytogenetic risks (p = 0.028), RUNX1 (p = 0.047) or transcription factor (TF) gene mutations (p = 0.011) than those without CKs, poor risk cytogenetics, RUNX1 and TF gene mutation.
conclusionsComplex karyotype was associated with poor ORR in MDS patients receiving azacitidine monotherapy, therefore, these patients need to be treated with the combination therapy or other treatment regimens rather than azacitidine monotherapy. CKs, intermediate/higher-risk IPSS-R, poor-cytogenetic risks, mutated RUNX1 and transcription factor gene mutations were associated with poor OS in MDS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.